Physician profile
Michael Campion
NPI 1265404503
$3,220.75
in general payments reported to CMS, 2019-2025
21 companies · $611 in 2025
The $611 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $221 · 2021: $105 · 2022: $111 · 2023: $437 · 2024: $1,090 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $897.00 | 2019-2025 | Hydrus Microstent, Clareon Panoptix Pro, Clareon |
| Carl Zeiss Meditec USA, INC. | $373.08 | 2024 | |
| Dompe US, INC. | $273.73 | 2019-2025 | Oxervate |
| Mallinckrodt Hospital Products INC. | $230.85 | 2020-2025 | Acthar |
| Rxsight INC | $198.25 | 2022-2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb Americas INC. | $196.97 | 2022-2025 | Xiidra, Envista Mx60 Iol, Miebo |
| Mallinckrodt Enterprises LLC | $150.84 | 2019 | |
| Novartis Pharmaceuticals Corporation | $131.00 | 2019-2022 | |
| Abbvie INC. | $119.31 | 2023-2025 | Alphagan P, Lumigan |
| Johnson & Johnson Surgical Vision, INC. | $117.45 | 2019 | |
| Horizon Therapeutics Plc | $96.57 | 2020-2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $95.02 | 2024-2025 | Omidria, Rayone Spheric, Rayone Emv |
| Kala Pharmaceuticals, INC. | $75.56 | 2020-2021 | |
| Glaukos Corporation | $43.39 | 2025 | Idosetr |
| Sun Pharmaceutical Industries INC. | $42.81 | 2019-2020 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $42.24 | 2023-2024 | Dextenza |
| Ani Pharmaceuticals, INC. | $38.23 | 2022-2025 | Yutiq |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.43 | 2021 | |
| Apellis Pharmaceuticals, INC. | $32.37 | 2025 | Syfovre |
| Sight Sciences, INC. | $16.32 | 2024 | Omni Surgical System |
| Oyster Point Pharma, INC. | $14.33 | 2024 | Tyrvaya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Campion listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.